Health & Medical Archives | Page 10 of 245 | Be Korea-savvy

Archive by category Health & Medical

Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities

Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability, and death caused by non-communicable diseases (NCDs). The start of the partnership was announced alongside the United Nations Global Assembly in [...]

Information on the total number of voting rights and shares: Nyxoah

Information on the total number of voting rights and shares: Nyxoah

Mont-Saint-Guibert (Belgium), September 27, 2024, 08:05 am CET / 2:05 am ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,907,711.21 Total number of securities carrying voting rights: [...]

Publication relating to transparency notifications: Nyxoah

Publication relating to transparency notifications: Nyxoah

Mont-Saint-Guibert (Belgium), September 27, 2024, 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On September 24, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons [...]

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved engraftment and bone marrow reconstitution potential of patient derived hematopoietic stem cells In vitro data also demonstrated improved ability to differentiate to erythroid cells, supporting potential for improvement in biomarkers of anemia HAIFA, Israel, Sept. 26 (Korea Bizwire) [...]

Boehringer Ingelheim expands cancer research at its Vienna site

Boehringer Ingelheim expands cancer research at its Vienna site

Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory space Over the past five years, Boehringer’s capital investments reached EUR 6.0 billion Boehringer Ingelheim is one of the world’s leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, [...]

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

SHANGHAI, Sept. 24, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that the European Commission (EC) has approved toripalimab (European trade name: LOQTORZI®) [...]

Impulse Dynamics Expands Executive Leadership Team

Impulse Dynamics Expands Executive Leadership Team

Extensive depth of experience comes with new leaders – Chief Operating Officer, Chief Financial Officer, Chief Administrative Officer and Chief Science and Strategy Officer Marlton, NJ, Sept. 24, 2024 (Korea Bizwire) – Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership appointments:   [...]

Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform

Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform

Opportunity for significant savings in energy consumption, reduction of paper and elimination of disposable batteries for telemetry revealed in Life Cycle Assessment Amsterdam, The Netherlands and Cambridge, Mass. and Miami, FL. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Jackson Health System, one of the nation’s largest public health systems in [...]

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an involuntary movement disorder that develops in around 15%-25% of patients taking antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder2,3 Data presented at the European [...]

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS) New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-‘749 [...]